Construction of a mathematical model for tuberculosis transmission in highly endemic regions of the Asia-pacific

Journal of Theoretical Biology

Volumn 358, Issue , 2014, Pages 74-84

  Trauer, James M ^a,b,c   Denholm, Justin T ^b,c   McBryde, Emma S ^a,b,c  

^a BURNET INSTITUTE   (Australia)

^b PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

BCG vaccine; Disease Transmission Infectious; Latent tuberculosis; Models Theoretical; Tuberculosis Multidrug Resistant

Indexed keywords

DISEASE TRANSMISSION; EPIDEMIOLOGY; INFECTIOUS DISEASE; NUMERICAL MODEL; TUBERCULOSIS; VACCINATION; VACCINE;

ARTICLE; BCG VACCINATION; COST; DISEASE TRANSMISSION; EXTRAPULMONARY TUBERCULOSIS; FITNESS COST; INFECTION RATE; LATENT TUBERCULOSIS; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MULTIDRUG RESISTANT TUBERCULOSIS; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIMULATION; TUBERCULOSIS CONTROL; ASIA; HUMAN; PACIFIC ISLANDS; THEORETICAL MODEL; TUBERCULOSIS;

PACIFIC OCEAN; PACIFIC RIM;

TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; ASIA; HUMANS; MODELS, THEORETICAL; PACIFIC ISLANDS; TUBERCULOSIS;

EID: 84902306156     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2014.05.023     Document Type: Article

References (64)

1. Abu-Raddad L.J., Sabatelli L., Achterberg J.T., Sugimoto J.D., Longini I.M., Dye C., Halloran M.E. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl. Acad. Sci. USA 2009, 106(33):13980-13985.
2. Aparicio J.P., Castillo-Chavez C. Mathematical modelling of tuberculosis epidemics. Math. Biosci. Eng. 2009, 6(2):209-237.
3. Aparicio J.P., Capurro A.F., Castillo-Chavez C. Transmission and dynamics of tuberculosis on generalized households. J. Theor. Biol. 2000, 206(3):327-341.
4. Aparicio J.P., Capurro A.F., Castillo-Chavez C. Markers of disease evolution: the case of tuberculosis. J. Theor. Biol. 2002, 215(2):227-237.
5. Bandera A., Gori A., Catozzi L., Degli Esposti A., Marchetti G., Molteni C., Ferrario G., Codecasa L., Penati V., Matteelli A., Franzetti F. Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. J. Clin. Microbiol. 2001, 39(6):2213-2218.
6. Basu S., Galvani A.P. The transmission and control of XDR TB in South Africa: an operations research and mathematical modelling approach. Epidemiol. Infect. 2008, 136(12):1585-1598.
7. Blower S.M., Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat. Med. 2004, 10(10):1111-1116.
8. Blower S.M., Small P.M., Hopewell P.C. Control strategies for tuberculosis epidemics: new models for old problems. Science 1996, 273(5274):497-500.
9. Blower S.M., McLean A.R., Porco T.C., Small P.M., Hopewell P.C., Sanchez M.A., Moss A.R. The intrinsic transmission dynamics of tuberculosis epidemics. Nat. Med. 1995, 1(8):815-821.
10. Borgdorff M.W., Sebek M., Geskus R.B., Kremer K., Kalisvaart N., van Soolingen D. The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach. Int. J. Epidemiol. 2011, 40(4):964-970.
11. Castillo-Chavez C., Feng Z. To treat or not to treat: the case of tuberculosis. J. Math. Biol. 1997, 35(6):629-656.
12. Castillo-Chavez C., Song B. Dynamic models of tuberculosis and their applications. Math. Biosci.d Eng. 2004, 1(2):361-404.
13. Cohen T., Sommers B., Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect. Dis. 2003, 3(1):13-21.
14. Cohen T., Colijn C., Finklea B., Murray M. Exogenous re-infection and the dynamics of tuberculosis epidemics: local effects in a network model of transmission. J. R. Soc .Interface 2007, 4(14):523-531.
15. Cohen T., Dye C., Colijn C., Williams B., Murray M. Mathematical models of the epidemiology and control of drug-resistant TB. Expert. Rev. Respir. Med. 2009, 3(1):67-79.
16. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., Mosteller F. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994, 271(9):698-702.
17. Colijn C., Cohen T., Murray M. Latent coinfection and the maintenance of strain diversity. Bull. Math. Biol. 2009, 71(1):247-263.
18. Cox H.S., Niemann S., Ismailov G., Doshetov D., Orozco J.D., Blok L., Rusch-Gerdes S., Kebede Y. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. Clin. Infect. Dis. 2007, 44(11):1421-1427.
19. Cross G.B., Coles K., Nikpour M., Moore O.A., Denholm J., McBryde E.S., Eisen D.P., Warigi B., Carter R., Pandey S., Harino P., Siba P., Coulter C., Mueller I., Phuanukoonnon S., Pellegrini M. TB incidence and characteristics in the remote gulf province of Papua New Guinea: a prospective study. BMC Infect. Dis. 2014, 14(1):93.
20. Das S., Paramasivan C.N., Lowrie D.B., Prabhakar R., Narayanan P.R. IS6110 restriction fragment length polymorphism typing of clinical isolates of Mycobacterium tuberculosis from patients with pulmonary tuberculosis in Madras, south India. Tuber Lung Dis. 1995, 76(6):550-554.
21. Diel R., Loddenkemper R., Niemann S., Meywald-Walter K., Nienhaus A. Negative and positive predictive value of a whole-blood interferon-gamma release assay for developing active tuberculosis: an update. Am. J. Respir. Crit. Care Med. 2011, 183(1):88-95.
22. Dowdy D.W., Dye C., Cohen T. Data needs for evidence-based decisions: a tuberculosis modeler[U+05F3]s 'wish list'. Int. J. Tuberc. Lung Dis. 2013, 17(7):866-877.
23. Dowdy D.W., Chaisson R.E., Maartens G., Corbett E.L., Dorman S.E. Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc. Natl. Acad. Sci. USA 2008, 105(32):11293-11298.
24. Dye C. The potential impact of new diagnostic tests on tuberculosis epidemics. Indian J. Med. Res. 2012, 135(5):737-744.
25. Dye C., Williams B.G. Eliminating human tuberculosis in the twenty-first century. J. R. Soc. Interface 2008, 5(23):653-662.
26. Dye C., Garnett G.P., Sleeman K., Williams B.G. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 1998, 352(9144):1886-1891.
27. Dye C., Williams B.G., Espinal M.A., Raviglione M.C. Erasing the world[U+05F3]s slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002, 295(5562):2042-2046.
28. Feng Z., Castillo-Chavez C., Capurro A.F. A model for tuberculosis with exogenous reinfection. Theor. Popul. Biol 2000, 57(3):235-247.
29. Feng Z., Huang W., Castillo-Chavez C. On the role of variable latent periods in mathematical models of tuberculosis. J. Dyn. Differ. Equ. 2001, 13(2):28.
30. Feng Z., Iannelli M., Milner F.A. A two-strain tuberculosis model with age of infection. SIAM J. Appl. Math. 2002, 62(5):1634-1656.
31. Fitzwater S.P., Caviedes L., Gilman R.H., Coronel J., LaChira D., Salazar C., Saravia J.C., Reddy K., Friedland J.S., Moore D.A. Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy. Clin. Infect. Dis. 2010, 51(4):371-378.
32. Gilpin C.M., Simpson G., Vincent S., O[U+05F3]Brien T.P., Knight T.A., Globan M., Coulter C., Konstantinos A. Evidence of primary transmission of multidrug-resistant tuberculosis in the Western Province of Papua New Guinea. Med. J. Aust. 2008, 188(3):148-152.
33. Gomes M.G., Aguas R., Lopes J.S., Nunes M.C., Rebelo C., Rodrigues P., Struchiner C.J. How host heterogeneity governs tuberculosis reinfection?. Proc. Biol. Sci. 2012, 279(1737):2473-2478.
34. Harries A.D., Hargreaves N.J., Gausi F., Kwanjana J.H., Salaniponi F.M. High early death rate in tuberculosis patients in Malawi. Int. J. Tuberc. Lung Dis. 2001, 5(11):1000-1005.
35. Hickson R.I., Mercer G.N., Lokuge K.M. A metapopulation model of tuberculosis transmission with a case study from high to low burden areas. PLoS One 2012, 7(4):e34411.
36. Lambert M.L., Hasker E., Van Deun A., Roberfroid D., Boelaert M., Van der Stuyft P. Recurrence in tuberculosis: relapse or reinfection?. Lancet Infect. Dis. 2003, 3(5):282-287.
37. MacIntyre C.R., Dwyer B., Streeton J.A. The epidemiology of tuberculosis in Victoria. Med. J. Aust. 1993, 159(10):672-677.
38. McBryde E.S., Denholm J.T. Risk of active tuberculosis in immigrants: effects of age, region of origin and time since arrival in a low-exposure setting. Med. J. Aust. 2012, 197(8):458-461.
39. Medical Research Council BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Bull. World Health Organ. 1972, 46(3):371-385.
40. Moolphate S., Aung M.N., Nampaisan O., Nedsuwan S., Kantipong P., Suriyon N., Hansudewechakul C., Yanai H., Yamada N., Ishikawa N. Time of highest tuberculosis death risk and associated factors: an observation of 12 years in Northern Thailand. Int. J. Gen. Med. 2011, 4:181-190.
41. Raleigh J.W., Wichelhausen R. Exogenous reinfection with Mycobacterium tuberculosis confirmed by phage typing. Am. Rev. Respir. Dis. 1973, 108(3):639-642.
42. ReVelle C.S., Lynn W.R., Feldmann F. Mathematical models for the economic allocation of tuberculosis control activities in developing nations. Am. Rev. Respir. Dis. 1967, 96(5):893-909.
43. Rodrigues P., Gomes M.G., Rebelo C. Drug resistance in tuberculosis-a reinfection model. Theor. Popul. Biol. 2007, 71(2):196-212.
44. Sahadevan R., Narayanan S., Paramasivan C.N., Prabhakar R., Narayanan P.R. Restriction fragment length polymorphism typing of clinical isolates of Mycobacterium tuberculosis from patients with pulmonary tuberculosis in Madras, India, by use of direct-repeat probe. J. Clin. Microbiol. 1995, 33(11):3037-3039.
45. Sergeev R., Colijn C., Cohen T. Models to understand the population-level impact of mixed strain Mycobacterium tuberculosis infections. J. Theor. Biol. 2011, 280(1):88-100.
46. Sergeev R., Colijn C., Murray M., Cohen T. Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis. Sci. Transl. Med.. 135ra167 2012, 4(135).
47. Sonnenberg P., Murray J., Glynn J.R., Shearer S., Kambashi B., Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001, 358(9294):1687-1693.
48. Sutherland I., Svandova E., Radhakrishna S. The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands. Tubercle 1982, 63(4):255-268.
49. Tiemersma E.W., van der Werf M.J., Borgdorff M.W., Williams B.G., Nagelkerke N.J. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS ONE [Electronic Resource] 2011, 6(4):e17601.
50. United Nations Department of Economic and Social Affairs/Population Division, 2012. World Population Prospects: The 2012 Revision, vol. 2, pp. 1-4.
51. van der Werf M.J., Langendam M.W., Huitric E., Manissero D. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur. Respir. J. 2012, 39(6):1511-1519.
52. van Rie A., Warren R., Richardson M., Victor T.C., Gie R.P., Enarson D.A., Beyers N., van Helden P.D. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N. Engl. J. Med. 1999, 341(16):1174-1179.
53. Verver S., Warren R.M., Beyers N., Richardson M., van der Spuy G.D., Borgdorff M.W., Enarson D.A., Behr M.A., van Helden P.D. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am. J. Respir. Crit. Care. Med. 2005, 171(12):1430-1435.
54. Vynnycky E., Fine P.E. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol. Infect. 1997, 119(2):183-201.
55. Waaler H., Geser A., Andersen S. The use of mathematical models in the study of the epidemiology of tuberculosis. Am. J. Publ. Health Nations Health 1962, 52:1002-1013.
56. World Bank, 2013. World Development Indicators.
57. World Health Organisation Treatment of Tuberculosis Guidelines 2010, WHO, Geneva, Switzerland.
58. World Health Organisation Global Health Observatory Data Repository, Data on the size of the HIV/AIDS epidemic: Prevalence of HIV among adults aged 15 to 49 (%) by country 2013, vol. 2013. World Health Organisation, Geneva, Switzerland.
59. World Health Organisation Global Health Observatory Data Repository. Life expectancy: Life expectancy by country 2011 2013, vol. 2013. World Health Organisation, Geneva, Switzerland.
60. World Health Organisation Global Tuberculosis Report 2013 2013, Vol. 2011. WHO, Geneva, Switzerland.
61. Wu P., Lau E.H., Cowling B.J., Leung C.C., Tam C.M., Leung G.M. The transmission dynamics of tuberculosis in a recently developed Chinese city. PLoS One 2010, 5(5):e10468.
62. Ziegler J.E., Edwards M.L., Smith D.W. Exogenous reinfection in experimental airborne tuberculosis. Tubercle 1985, 66(2):121-128.
63. Ziv E., Daley C.L., Blower S.M. Early therapy for latent tuberculosis infection. Am. J. Epidemiol. 2001, 153(4):381-385.
64. Zumla A., Abubakar I., Raviglione M., Hoelscher M., Ditiu L., McHugh T.D., Squire S.B., Cox H., Ford N., McNerney R., Marais B., Grobusch M., Lawn S.D., Migliori G.B., Mwaba P., O[U+05F3]Grady J., Pletschette M., Ramsay A., Chakaya J., Schito M., Swaminathan S., Memish Z., Maeurer M., Atun R. Drug-resistant tuberculosis-current dilemmas, unanswered questions, challenges, and priority needs. J. Infect. Dis. 2012, 205(Suppl 2):S228-S240.